Cirrhosis with non alcoholic steatohepatitis: role of tamoxifen
Dray, X.; Tainturier, M.H.; De La Lande, P.; Marty, O.; Mallet, L.
Gastroenterologie Clinique et Biologique 24(11): 1122-1123
2000
ISSN/ISBN: 0399-8320 PMID: 11139682 Document Number: 521474
We report a case of non-alcoholic steatohepatitis with cirrhosis in a woman receiving tamoxifen as adjuvant treatment for breast cancer. Despite the presence of other risk factors for non-alcoholic steatohepatitis (such as diabetes, obesity and hyperlipidemia), the patient developed non-alcoholic steatohepatitis and cirrhosis only after tamoxifen was started. We suggest that patients receiving tamoxifen, especially patients with predisposing metabolic disorders, should be evaluated for non-alcoholic steatohepatitis, because progression to cirrhosis may occur.